91st European Atherosclerosis Society Congress 2023
SANTORINI data support PCSK9i combinations for high risk patients
New 12 month follow up data from the SANTORINI study of lipid-lowering therapy (LLT) use in patients at high or very high cardiovascular (CV) risk show an average LDL-C reduction of 0.4 mmol/L, driven by fewer patients on no LLT and greater use of combination…
read more »
High Lp(a) linked to plaque progression over 10 years
Patients with high Lp(a) levels have up to 50% increased coronary plaque burden and markedly increased coronary artery disease (CAD) progression, according to data on 272 patients with suspected CAD who underwent repeat coronary CT angiography (CCTA) at a median 10-year follow-up. Scans were analysed…
read more »
PERI-DYS study suggests need for greater LLT intensification
Infrequent intensification of lipid lowering therapy (LLT) may explain low LDL-C goal achievement (<55 mg/dL) in patients at very high cardiovascular risk in the PERI-DYS study, conclude the study authors. In this prospective observational study, 810/1,713 (47.3%) patients at 70 sites in Germany were receiving…
read more »
Latest insights from CLEAR Outcomes
The CLEAR Outcomes trial provides a sound rationale for the use of bempedoic acid to reduce major cardiovascular (CV) outcomes in patients intolerant to statins, concluded Prof Stephen Nicholls (Monash University, Melbourne, Australia). “Management of patients unable or unwilling to take statins represents a challenging…
read more »
